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Cutting Edge: CD1d Restriction and Th1/Th2/Th17
Cytokine Secretion by Human Vd3 T Cells
Bozgana A. Mangan,* Margaret R. Dunne,* Vincent P. O’Reilly,* Pa´draic J. Dunne,*
Mark A. Exley,† Donal O’Shea,‡,x Emmanuel Scotet,{ Andrew E. Hogan,‡,x,1 and
Derek G. Doherty*,1
Human gd T cells expressing the Vd3 TCR make up
a minor lymphocyte subset in blood but are enriched in
liver and in patients with some chronic viral infections
and leukemias. We analyzed the frequencies, pheno-
types, restriction elements, and functions of fresh and
expanded peripheral blood Vd3 T cells. Vd3 T cells
accounted for ∼0.2% of circulating T cells, included
CD4+, CD8+, and CD42CD82 subsets, and variably
expressed CD56, CD161, HLA-DR, and NKG2D but
neither NKG2A nor NKG2C. Vd3 T cells were sorted
and expanded by mitogen stimulation in the presence
of IL-2. Expanded Vd3 T cells recognized CD1d but
not CD1a, CD1b, or CD1c. Upon activation, they
killed CD1d+ target cells, released Th1, Th2, and Th17
cytokines, and induced maturation of dendritic cells
into APCs. Thus, Vd3 T cells are glycolipid-reactive
T cells with distinct Ag specificities but functional sim-
ilarities to NKT cells. The Journal of Immunology,
2013, 191: 30–34.
I
n addition to conventional MHC-restricted T cells, a
number of innate T cell populations that recognize
nonpeptide Ags in an MHC-unrestricted manner have
been described in mice and humans. Invariant NKT (iNKT)
cells express a TCR composed of an invariant a-chain
(Va24Ja18 in humans and Va14Ja18 in mice) that pairs
with a limited number of b-chains and recognize glycolipid
Ags presented by the MHC class I–like molecule CD1d (1,
2). Mucosal-associated invariant T (MAIT) cells express an
invariant Va7.2-Ja33 TCR in humans (Va19-Ja33 in mice)
and recognize microbial vitamin B metabolites presented by
MR1 (3). Recently, a second CD1d-restricted T cell pop-
ulation, invariant Va10-Ja50 TCR a-chains with a distinct
glycolipid Ag specificity, was described in mice (4). The most
abundant innate T cells in humans are gd T cells, of which
there are two major subsets. Vg9Vd2 T cells recognize py-
rophosphate intermediates of isoprenoid synthesis in certain
bacteria (5), and Vd1 T cells can be activated by CD1c,
CD1d, or the stress-inducible molecule MICA/B expressed by
virus-infected and tumor cells (6–8).
Innate T cells can respond to ligand stimulation by rapidly
and potently killing target cells, by releasing cytokines that
polarize adaptive immune responses, and by transactivating
NK cells, dendritic cells (DCs), and B cells (1–3, 5, 9–12).
iNKT cells can prevent disease in animal models (1, 2). Hu-
man iNKT cells and Vg9Vd2 T cells display potent antitumor
activity in vitro and are currently being tested as adjuvants for
cellular immunotherapies in clinical trials for cancer (13, 14).
The majority of non-Vd1 and non-Vg9Vd2 gd T cells in
humans express the Vd3 TCR chain. The ligand specificities
of Vd3 T cells are unknown, but these cells are reported to be
expanded in peripheral blood of renal and stem cell transplant
recipients with CMV activation (15–17), in patients with
HIV infection (18) or B cell chronic lymphocytic leukemia
(19), and in healthy livers (20). In this study, we enumerated
and phenotyped Vd3 T cells from human peripheral blood
and developed a method for their expansion ex vivo. We show
that Vd3 T cells include cells that recognize CD1d and re-
spond by killing CD1d+ target cells, releasing Th1, Th2, and
Th17 cytokines and promoting maturation of DC into APCs.
Thus, Vd3 T cells include CD1d-restricted T cells with
functional similarities, but distinct Ag specificities, to those of
iNKT cells, properties that place Vd3 T cells as candidate
targets for therapeutic immunomodulation.
Materials and Methods
Enumeration and phenotyping of Vd3 T cells
PBMCs were isolated from healthy donors. Vd3 T cells were enumerated and
phenotyped by staining PBMCs with an anti-Vd3 TCR mAb (clone P11.5B;
Beckman Coulter) and mAbs specific for CD3, CD3, CD4, CD8, CD25,
CD28, CD56, CD69, CD161, HLA-DR, NKG2A, NKG2C, and NKG2D,
as well as the Va24Ja18 TCR expressed by iNKT cells. Cells were acquired
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using a Cyan flow cytometer (Beckman Coulter) and analyzed using FlowJo
(TreeStar) using fluorescence-minus-one controls.
Generation of Vd3 T cell and iNKT cell lines
Vd3 T cells were enriched from PBMCs by sorting of Vd3+CD3+ cells using
a MoFlo XDP Cell Sorter (Beckman Coulter). A total of 1000 Vd3 T cells
was cultured in RPMI 1640 medium containing 0.05 mM L-glutamine, 10%
v/v HyClone FBS, 0.02 M HEPES buffer, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2.5 mg/ml amphotericin B Fungizone. Cells were stimu-
lated with 1 mg/ml PHA-P and 250 U/ml IL-2 in the presence of excess (2 3
105) irradiated allogeneic PBMCs, prepared from two donors. After 24 and
48 h, medium was replaced with fresh medium containing 250 U/ml IL-2.
Vd3 cells were expanded for 2–4 wk in the presence of IL-2. Purity and
phenotype of Vd3 T cell lines were assessed by flow cytometry. iNKT cell
lines were generated and characterized as described previously (21).
Analysis of CD1 recognition and effector function of Vd3 T cell lines
Expanded Vd3 T cells or iNKT cells were cocultured with equal numbers of
mock-transfected HeLa cells or HeLa cell–expressing transfected CD1a,
CD1b, CD1c, or CD1d in the absence or presence of the iNKT cell agonist
glycolipid a-galactosylceramide (a-GC; 100 ng/ml), PMA (1 ng/ml), and
blocking mAbs against CD1d and Vd3 (clones 42.1 and P11.5B) or isotype
control Ab (10 mg/ml). As positive controls, cells were stimulated with 10 ng/
ml PMA and 1 mg/ml ionomycin. Vd3 T cell activation was measured by flow
cytometric analysis of cell surface expression of the marker of cytolytic degran-
ulation, CD107a, and intracellular production of cytokines, as described (21).
Levels of cytokines released into cell supernatants were measured by ELISA.
Analysis of adjuvant effects of Vd3 T cell lines for DCs
Monocyte-derived DCs were generated by culturing magnetic bead–enriched
CD14+ monocytes for 6 d with GM-CSF and IL-4 (11). Immature DCs were
then cultured with equal numbers of expanded Vd3 T cells or 1 mg/ml LPS in
the absence or presence of blocking mAbs against CD1d, Vd3, CD40, or
CD40L or isotype-control Ab (10 mg/ml). The expression by the DCs of
molecules commonly found on APCs (CD40, CD54, CD80, CD83, CCR7,
and HLA-DR) was analyzed after 3 d by flow cytometry. Cytokine release (IL-
10 and IL-12) was measured by ELISA. The capacity of DCs, cultured for
3 d in the absence or presence of Vd3 T cells or LPS, to drive proliferation of
naive alloreactive T cells was determined by labeling the T cells with CellTrace
Violet (Invitrogen) and analyzing dye dilution after 6 d by flow cytometry.
Statistical analysis
Groups were compared using the Mann–Whitney U test or Student t test, as
appropriate. The p values , 0.05 were considered statistically significant.
Results and Discussion
Frequency and phenotype of fresh Vd3 T cells
Flow cytometric analysis of CD3 and Vd3 TCR expression by
PBMCs from 20 healthy donors revealed that Vd3 T cells
account for 0.2 6 0.3% (mean 6 SEM) of peripheral T cells
(Fig. 1A). This compares with ∼0.05% for human iNKT cells
(2, 21), ∼3% for Vg9Vd2 T cells (5, 11), and up to 10% for
MAIT cells (3) in blood. Phenotypic analysis showed that
fresh Vd3 T cells can express CD4 or CD8, but the majority
(69 6 19%) were double negative for CD4 and CD8 (DN)
FIGURE 1. Frequencies and phenotypes of human Vd3 T cells. (A)
Scatterplot showing percentages of freshly isolated circulating CD3+ cells
from 20 healthy donors that express the Vd3 TCR chain, as detected by flow
cytometry. (B) Percentages of circulating Vd3 T cells from nine healthy
donors that express CD4, CD8, or neither (DN). (C) Percentages of circu-
lating Vd3 T cells from nine healthy donors that express NKG2A, NKG2C,
NKG2D CD56, CD28, CD69, HLA-DR, CD161, and CD25. Horizontal
lines represents the means.
FIGURE 2. Ex vivo expansion of human Vd3 T cells. (A) Flow cytometric
dot plots showing the expression of CD3 and the Vd3 TCR by fresh PBMCs
(left panel ) and by sorted and expanded Vd3 T cells (second panel ) and the
expression of NKG2C (third panel ), NKG2D (fourth panel ), and CD4 and
CD8 (right panel ) by expanded Vd3 T cells. (B) Kinetics of mitogen-stimu-
lated Vd3 T cell expansion starting with 1000 sorted Vd3 T cells. (C) Per-
centages of Vd3 T cells expanded from five healthy donors that express CD4,
CD8, neither CD4 nor CD8 (DN), CD56, CD94, CD161, NKG2D, or
NKG2C. Horizontal lines represent the means.
FIGURE 3. Vd3 T cells recognize CD1d. (A) Mean percentages of Vd3
T cells expanded from five donors that externalize CD107a after culturing for
4 h in medium alone, with HeLa cells expressing CD1a, CD1b, CD1c, or
CD1d, or with mock-transfected HeLa cells in the absence and presence of
PMA. (B) Mean percentages of expanded Vd3 T cells from three donors that
degranulate in response to HeLa-CD1d in the absence and presence of PMA
and mAbs specific for CD1d (a-CD1d) or Vd3 (a-Vd3). (C) Mean per-
centages of Vd3 T cells or iNKT cells from five donors that degranulate in
response to HeLa-CD1d cells in the absence and presence of a-GC. Error
bars represent SEM.
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(Fig. 1B). Interestingly, CD4+, CD8+, and DN cell subsets are
also found within iNKT cells, Vg9Vd2 T cells, and MAIT cells,
and they have distinct functional activities (3, 11, 21). Like
other innate T cells, most fresh Vd3 T cells expressed the NK
cell–associated receptors NKG2D, CD56, and CD161 but not
NKG2A or NKG2C. Most displayed phenotypes of resting
T cells, being CD28+ and CD252CD692, whereas HLA-DR
was variably expressed (Fig. 1C). Therefore, human Vd3 T cells
are similar to other innate T cell populations in that they display
phenotypic heterogeneity with regard to their expression of NK
cell–associated receptors and CD4 and CD8.
Expansion of Vd3 T cells in vitro
Because of their low frequencies in peripheral blood, Vd3
T cells need to be expanded ex vivo to obtain sufficient
numbers for functional studies or for clinical use. We tried
a number of T cell–expansion protocols and found that a
single stimulation of sorted Vd3 T cells with PHA in the pre-
sence of irradiated feeder cells, followed by culturing with
IL-2, was optimal. This method yielded up to 25 million Vd3
T cells from as few as 1000 cells in 14 d and with purities
.95% (Fig. 2A, 2B). Phenotypic analysis of Vd3 T cell lines
from five donors showed that the CD4/CD8/DN dis-
tributions of expanded Vd3 T cells were similar to those of
fresh Vd3 T cells. Expanded Vd3 T cells also retained ex-
pression of NKG2D, were negative for NKG2C, and had
lower frequencies of CD56 and CD161 expression than did
fresh Vd3 T cells (Fig. 2A, 2C). Thus, highly pure Vd3 T cells
can be readily expanded by mitogen stimulation in vitro.
Vd3 T cells recognize CD1d
A significant fraction of human T cells, including gd T cells,
recognize autoantigens presented by CD1a, CD1b, CD1c, or
CD1d (4, 6–8, 22–24). We investigated whether expanded
Vd3 T cells could recognize and kill target cells expressing CD1
isotypes by coculturing them with mock-transfected HeLa
cells or HeLa cells expressing transfected CD1a, CD1b, CD1c,
or CD1d and measuring the expression of the degranulation
marker CD107a. In the absence of added glycolipid, Vd3
T cells degranulated in response to HeLa cells expressing CD1d
but not CD1a, CD1b, or CD1c (Fig. 3A). The requirement
for CD1d was confirmed in blocking experiments in which
anti-CD1d mAb abrogated degranulation in response to CD1d
alone but not CD1d + PMA (Fig. 3B). In contrast, treatment
with an anti-Vd3 mAb did not prevent Vd3 T cell activation.
Future studies are required to determine whether this mAb can
block or stimulate Vd3 T cell activation.
Many CD1d-restricted T cells do not express the Va24Ja18
TCR found on iNKT cells or recognize the CD1d-binding
glycolipid a-GC (4, 8, 24) and are termed type 2 NKT cells.
We analyzed the coexpression of the Vd3 and Va24Ja18
TCR chains by PBMCs, expanded Vd3 T cells, or expanded
iNKT cells and found that these TCR chains were never
coexpressed by the same cells (data not shown), indicating
that Vd3 T cells are not iNKT cells. Vd3 T cell responses to
CD1d were not augmented by adding a-GC, as was seen
when iNKT cells were used (Fig. 3C), indicating that Vd3
and iNKT cells have distinct Ag specificities. Thus, some (if
FIGURE 4. Vd3 T cells produce multiple cytokines upon stimulation with
PMA and ionomycin or CD1d+ cells. (A) Flow cytometric dot plots showing
expression of IFN-g, TNF-a, IL-4, IL-10, or IL-17 by expanded Vd3 T cell
lines after stimulation for 4 h with PMA and ionomycin. Results are repre-
sentative of data using expanded Vd3 T cells from six donors. (B) Mean levels
of IFN-g and IL-17 released by expanded Vd3 T cells from four donors after
stimulation for 24 h with mock-transfected HeLa cells or HeLa-CD1d cells in
the absence or presence of PMA and blocking anti-CD1d mAb. No blocking
was seen when isotype-matched control Ab was used (data not shown). Error
bars represent SEM.
FIGURE 5. Vd3 T cells induce DC maturation. (A) Mean fluorescence intensities (MFI) of expression of CD40 and CD86 by monocyte-derived DCs after
culturing them for 3 d in medium alone, with LPS, or with equal numbers of Vd3 T cells in the absence and presence of blocking mAbs against CD1d, Vd3, CD40,
or CD40L. Results are means of five different DC–Vd3 T cell combinations. Error bars represent SEM. (B) Levels of IL-10 and IL-12 released by DCs or Vd3 T cells
cultured alone for 2 d, DCs cultured with LPS, and DCs cultured with Vd3 T cells. Results are means of three experiments using different DCs and Vd3 T cells. (C)
Proliferation of naive allogeneic T cells in response to medium alone, immature DCs, or DCs matured for 24 h with LPS or Vd3 T cells. T cells were labeled with
CellTrace Violet before adding to the DCs. Results show representative flow cytometry graphs (from four experiments) showing CellTrace dye dilution after 6 d.
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not all) Vd3 T cells fit the definition of type 2 NKT cells.
CD1d-restricted activation by other glycolipids, including sul-
phatide and cardiolipin, was reported for human Vd1 T cells
(7, 8) and murine gd T cells (25).
Cytokine production by Vd3 T cells
A notable feature of innate T cells is their capacity to rapidly
secrete large amounts of Th cell–polarizing cytokines that can
skew adaptive immune responses. iNKT cells can secrete Th1,
Th2, Th17, and regulatory T cell cytokines, sometimes si-
multaneously (1, 2, 21), whereas Vg9Vd2 T cells most readily
produce Th1 cytokines but can be induced, under certain
conditions, to produce Th2 and Th17 cytokines (5, 11), and
MAIT cells can produce Th1 and Th17 cytokines (3). We
examined intracellular production of IFN-g, TNF-a, IL-4,
IL-10, IL-13, and IL-17 by expanded Vd3 T cells stimu-
lated with HeLa cells expressing CD1d or PMA and ion-
omycin. Fig. 4A shows that some Vd3 T cells produced IFN-
g, TNF-a, IL-4, or IL-17, but not IL-10, indicating that like
iNKT cells, they can promote Th1, Th2, and Th17 responses.
CD1d-dependent release of IFN-g and IL-17 by Vd3 T cells
into cell supernatants was also shown by ELISA (Fig. 4B) and
found to be blocked by treatment with anti-CD1d, but not
isotype-control, Ab. Thus, like other innate T cells, Vd3 T cells
can regulate adaptive immune responses via production of mul-
tiple Th-polarizing cytokines.
DC maturation by Vd3 T cells
iNKT cells and Vg9Vd2 T cells can drive the differentiation
of immature DCs into APCs (1, 9, 11), and this property led
to their testing as adjuvants in DC-based immunotherapies
(13, 14). We tested whether Vd3 T cells can similarly induce
DC maturation in vitro. Immature monocyte-derived DCs
were cocultured for 3 d alone or with equal numbers of ex-
panded Vd3 T cells from four donors or LPS, and the ex-
pression of the APC markers CD40, CD54, CD80, CD83,
CCR7, and HLA-DR by DCs was analyzed by flow cytom-
etry. We found that Vd3 T cells upregulated CD40, CD83,
CD86, and HLA-DR expression by DCs to levels comparable
to LPS-stimulated DCs. CD80, CCR7, and CD54 were not
upregulated (Fig. 5A shows data for CD40 and CD86). In-
clusion of blocking mAbs showed that Vd3 T cell–mediated
DC maturation required CD1d but not CD40–CD40L
interactions. Vd3 T cells also induced IL-10 and IL-12 pro-
duction by DCs (Fig. 5B), and Vd3 T cell–matured DCs
induced increased proliferation of naive alloreactive T cells
compared with immature DCs (Fig. 5C). These findings ar-
gue that some (if not all) Vd3 T cells promote maturation of
DCs into APCs capable of activating naive T cells.
Concluding remarks
We identified Vd3 TCR+ T cells as a novel population of
human CD1d-restricted T cells whose glycolipid specificities
are distinct from those of iNKT cells. Like iNKT cells, acti-
vated Vd3 T cells kill CD1d+ cells, release Th1, Th2, and
Th17 cytokines, and promote maturation of DCs into APCs.
Future studies are required to find out whether, like iNKT cells,
Vd3 T cells can be targeted for tumor immunotherapy; how-
ever, two studies (16, 26) showed that they can kill tumor
intestinal epithelial cells but not healthy epithelial cells. Because
CD4+, CD8+, and DN subsets of iNKT cells have distinct
cytokine profiles (21), it is likely that a functional comparison
of CD4+, CD8+, and DN Vd3 T cell subsets will be required to
identify the optimal antitumor cells.
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